These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Pharmacokinetics of subcutaneous immunoglobulin and their use in dosing of replacement therapy in patients with primary immunodeficiencies. Berger M; Rojavin M; Kiessling P; Zenker O Clin Immunol; 2011 May; 139(2):133-41. PubMed ID: 21353644 [TBL] [Abstract][Full Text] [Related]
10. Subcutaneous immunoglobulin therapy by rapid push is preferred to infusion by pump: a retrospective analysis. Shapiro R J Clin Immunol; 2010 Mar; 30(2):301-7. PubMed ID: 20082124 [TBL] [Abstract][Full Text] [Related]
11. Clinical Profile, Dosing, and Quality-of-Life Outcomes in Primary Immune Deficiency Patients Treated at Home with Immunoglobulin G: Data from the IDEaL Patient Registry. Kearns S; Kristofek L; Bolgar W; Seidu L; Kile S J Manag Care Spec Pharm; 2017 Apr; 23(4):400-406. PubMed ID: 28345437 [TBL] [Abstract][Full Text] [Related]
12. Evaluating dose ratio of subcutaneous to intravenous immunoglobulin therapy among patients with primary immunodeficiency disease switching to 20% subcutaneous immunoglobulin therapy. Krishnarajah G; Lehmann JK; Ellman B; Bhak RH; DerSarkissian M; Leader D; Bullinger AL; Sheng Duh M Am J Manag Care; 2016 Oct; 22(15 Suppl):s475-s481. PubMed ID: 27849353 [TBL] [Abstract][Full Text] [Related]
13. Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal dose. Berger M Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):532-8. PubMed ID: 21971330 [TBL] [Abstract][Full Text] [Related]
14. Subcutaneous immunoglobulin therapy given by subcutaneous rapid push vs infusion pump: a retrospective analysis. Shapiro RS Ann Allergy Asthma Immunol; 2013 Jul; 111(1):51-5. PubMed ID: 23806460 [TBL] [Abstract][Full Text] [Related]
15. Subcutaneous immunoglobulin (16 or 20%) therapy in obese patients with primary immunodeficiency: a retrospective analysis of administration by infusion pump or subcutaneous rapid push. Shapiro R Clin Exp Immunol; 2013 Aug; 173(2):365-71. PubMed ID: 23607310 [TBL] [Abstract][Full Text] [Related]
16. Rapid subcutaneous IgG replacement therapy is effective and safe in children and adults with primary immunodeficiencies--a prospective, multi-national study. Gardulf A; Nicolay U; Asensio O; Bernatowska E; Böck A; Carvalho BC; Granert C; Haag S; Hernández D; Kiessling P; Kus J; Pons J; Niehues T; Schmidt S; Schulze I; Borte M J Clin Immunol; 2006 Mar; 26(2):177-85. PubMed ID: 16758340 [TBL] [Abstract][Full Text] [Related]
17. Subcutaneous immunoglobulins replacement therapy in secondary antibody deficiencies: Real life evidence as compared to primary antibody deficiencies. Cinetto F; Neri R; Vianello F; Visentin A; Barilà G; Gianese S; Lanciarotta A; Milito C; Rattazzi M; Piazza F; Trentin L; Zambello R; Agostini C; Scarpa R PLoS One; 2021; 16(3):e0247717. PubMed ID: 33661940 [TBL] [Abstract][Full Text] [Related]
18. Cost-minimization analysis of IgPro20, a subcutaneous immunoglobulin, in Japanese patients with primary immunodeficiency. Igarashi A; Kanegane H; Kobayashi M; Miyawaki T; Tsutani K Clin Ther; 2014 Nov; 36(11):1616-24. PubMed ID: 25236916 [TBL] [Abstract][Full Text] [Related]
19. Subcutaneous Immunoglobulin Therapy for Hypogammaglobulinemia Secondary to Malignancy or Related Drug Therapy. Windegger TM; Lambooy CA; Hollis L; Morwood K; Weston H; Fung YL Transfus Med Rev; 2017 Jan; 31(1):45-50. PubMed ID: 27450021 [TBL] [Abstract][Full Text] [Related]
20. Subcutaneous immunoglobulin replacement therapy with Hizentra, the first 20% SCIG preparation: a practical approach. Jolles S; Sleasman JW Adv Ther; 2011 Jul; 28(7):521-33. PubMed ID: 21681653 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]